[go: up one dir, main page]

WO2022067269A3 - Anticorps contre le sars-cov-2 - Google Patents

Anticorps contre le sars-cov-2 Download PDF

Info

Publication number
WO2022067269A3
WO2022067269A3 PCT/US2021/052481 US2021052481W WO2022067269A3 WO 2022067269 A3 WO2022067269 A3 WO 2022067269A3 US 2021052481 W US2021052481 W US 2021052481W WO 2022067269 A3 WO2022067269 A3 WO 2022067269A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
antigen
sars
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/052481
Other languages
English (en)
Other versions
WO2022067269A2 (fr
Inventor
Davide Corti
Anna De Marco
Matteo Samuele PIZZUTO
Barbara GUARINO
Florian LEMPP
Alex Chen
Laura ROSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Priority to JP2023544186A priority Critical patent/JP2023545322A/ja
Priority to EP21806447.5A priority patent/EP4217385A2/fr
Priority to CA3194162A priority patent/CA3194162A1/fr
Priority to BR112023005684A priority patent/BR112023005684A2/pt
Publication of WO2022067269A2 publication Critical patent/WO2022067269A2/fr
Publication of WO2022067269A3 publication Critical patent/WO2022067269A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci qui peuvent se lier à un antigène du SARS-CoV-2 et, dans certains modes de réalisation, peuvent neutraliser une infection par le SARS-CoV-2. Dans certains modes de réalisation, un anticorps ou un fragment de liaison à l'antigène est capable de se lier à une protéine de spicule du SARS-CoV-2 dans le domaine N-terminal (NTD). L'invention concerne également des polynucléotides qui codent pour un anticorps ou un fragment de liaison à l'antigène, des vecteurs qui comprennent un polynucléotide, des cellules hôtes qui expriment un anticorps ou un fragment de liaison à l'antigène, des compositions pharmaceutiques et des méthodes de traitement ou de diagnostic d'une infection par le SARS-CoV-2.
PCT/US2021/052481 2020-09-28 2021-09-28 Anticorps contre le sars-cov-2 Ceased WO2022067269A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2023544186A JP2023545322A (ja) 2020-09-28 2021-09-28 Ｓａｒｓ－ｃｏｖ－２に対する抗体
EP21806447.5A EP4217385A2 (fr) 2020-09-28 2021-09-28 Anticorps contre le sars-cov-2
CA3194162A CA3194162A1 (fr) 2020-09-28 2021-09-28 Anticorps contre le sars-cov-2
BR112023005684A BR112023005684A2 (pt) 2020-09-28 2021-09-28 Anticorpos contra sars-cov-2

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202063084501P 2020-09-28 2020-09-28
US63/084,501 2020-09-28
US202063111435P 2020-11-09 2020-11-09
US63/111,435 2020-11-09
US202063112505P 2020-11-11 2020-11-11
US63/112,505 2020-11-11
US202063119545P 2020-11-30 2020-11-30
US63/119,545 2020-11-30
US202163137112P 2021-01-13 2021-01-13
US63/137,112 2021-01-13
US202163170356P 2021-04-02 2021-04-02
US63/170,356 2021-04-02

Publications (2)

Publication Number Publication Date
WO2022067269A2 WO2022067269A2 (fr) 2022-03-31
WO2022067269A3 true WO2022067269A3 (fr) 2022-06-23

Family

ID=78599130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/052481 Ceased WO2022067269A2 (fr) 2020-09-28 2021-09-28 Anticorps contre le sars-cov-2

Country Status (5)

Country Link
EP (1) EP4217385A2 (fr)
JP (1) JP2023545322A (fr)
BR (1) BR112023005684A2 (fr)
CA (1) CA3194162A1 (fr)
WO (1) WO2022067269A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201256A1 (fr) * 2022-04-12 2023-10-19 Vir Biotechnology, Inc. Thérapies par anticorps à haute dose contre une infection par le sars-cov-2
CN114805564B (zh) * 2022-06-10 2023-06-06 郑州大学 特异性识别SARS-CoV-2 S蛋白NTD区域的单克隆抗体及应用
WO2024036313A2 (fr) * 2022-08-12 2024-02-15 The Rockefeller University Anticorps anti-sars-cov-2 et procédés d'utilisation associés

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303280A (zh) * 2020-03-22 2020-06-19 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1597280B2 (fr) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Production d'anticorps monoclonaux par transformation de lymphocytes b par le virus d'epstein barr
DE602004030700D1 (de) 2003-09-24 2011-02-03 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin-like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008042814A2 (fr) 2006-09-29 2008-04-10 California Institute Of Technology Récepteurs mart-1 des lymphocytes t
NZ720353A (en) 2013-12-30 2019-12-20 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
JP6587696B2 (ja) 2015-05-13 2019-10-09 ズムトール バイオロジクス、インコーポレイテッド アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
WO2019024979A1 (fr) 2017-07-31 2019-02-07 Institute For Research In Biomedicine Anticorps à domaines fonctionnels dans la région de coude
MY202919A (en) 2017-09-22 2024-05-29 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303280A (zh) * 2020-03-22 2020-06-19 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHI XIANGYANG ET AL: "A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2", SCIENCE, vol. 369, no. 6504, 7 August 2020 (2020-08-07), US, pages 650 - 655, XP055850542, ISSN: 0036-8075, DOI: 10.1126/science.abc6952 *
EROSHENKO NIKOLAI ET AL: "Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 38, no. 7, 5 June 2020 (2020-06-05), pages 789 - 791, XP037187546, ISSN: 1087-0156, [retrieved on 20200605], DOI: 10.1038/S41587-020-0577-1 *
F. MIMOTO ET AL: "Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131", PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 26, no. 10, 5 June 2013 (2013-06-05), pages 589 - 598, XP055087986, ISSN: 1741-0126, DOI: 10.1093/protein/gzt022 *
KEVIN O. SAUNDERS ET AL: "Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life", FRONTIERS IN IMMUNOLOGY, vol. 10, 1 January 2019 (2019-01-01), pages 1296, XP055654839, DOI: 10.3389/fimmu.2019.01296 *
PINTO DORA ET AL: "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 583, no. 7815, 18 May 2020 (2020-05-18), pages 290 - 295, XP037289888, ISSN: 0028-0836, [retrieved on 20200518], DOI: 10.1038/S41586-020-2349-Y *
SHI RUI ET AL: "A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 584, no. 7819, 26 May 2020 (2020-05-26), pages 120 - 124, XP037211681, ISSN: 0028-0836, [retrieved on 20200526], DOI: 10.1038/S41586-020-2381-Y *
TORTORICI M ALEJANDRA ET AL: "Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms", SCIENCE, 24 September 2020 (2020-09-24), United States, pages 950 - 957, XP055794998, Retrieved from the Internet <URL:https://science.sciencemag.org/content/sci/370/6519/950.full.pdf> [retrieved on 20210414], DOI: 10.1126/science.abe3354 *
ZHANG LI ET AL: "A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2", BIORXIV, 23 September 2020 (2020-09-23), pages 1 - 18, XP055876862, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.09.23.309294v1.full.pdf> [retrieved on 20220107], DOI: 10.1101/2020.09.23.309294 *

Also Published As

Publication number Publication date
BR112023005684A2 (pt) 2023-11-07
JP2023545322A (ja) 2023-10-27
EP4217385A2 (fr) 2023-08-02
CA3194162A1 (fr) 2022-03-31
WO2022067269A2 (fr) 2022-03-31

Similar Documents

Publication Publication Date Title
EP4245373A3 (fr) Anticorps contre le sars-cov-2
BR112022015374A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
BR112022020706A2 (pt) Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
PH12022500020A1 (en) Antibodies against sars-cov-2
WO2022067269A3 (fr) Anticorps contre le sars-cov-2
MX2021005708A (es) Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
WO2019165122A8 (fr) Anticorps neutralisants dirigés contre la protéine d&#39;enveloppe (env) du vih-1 et leur utilisation
MY197648A (en) Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2019060750A3 (fr) Compositions d&#39;anticorps a33 et leurs méthodes d&#39;utilisation en radioimmunothérapie
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
CR20220646A (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
MX2023009244A (es) Anticuerpos contra la proteina espicular de coronavirus.
SA523451800B1 (ar) Sirp أجسام مضادة لـ ألفا
WO2022032003A3 (fr) Anticorps anti-claudine 18.2 et leurs utilisations
BRPI0606790C1 (pt) anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, composição, vetor de expressão, microrganismo transgênico, célula hospedeira procariótica, kit, e, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, ou de uma composição
WO2020172621A8 (fr) Anticorps anti-cd33 et leurs procédés d&#39;utilisation pour traiter le cancer
ZA202201464B (en) Anti-tigit antibodies and application thereof
WO2022020234A3 (fr) Dosage immunologique pour anticorps neutralisant le sars-cov-2 et matériaux correspondants
WO2022108976A3 (fr) Anticorps anti-gpa33 multispécifiques et leurs utilisations
BR112021017860A2 (pt) Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica
MX2022012021A (es) Peptidos de dominios knob autonomos.
WO2024020590A3 (fr) Molécules de liaison à l&#39;antigène ciblant la lymphopoïétine stromale thymique (tslp)
ZA202308460B (en) Anti-pd-1 antibody and use thereof
WO2022159839A8 (fr) Anticorps monoclonaux contre les coronavirus et leurs utilisations
WO2023159187A3 (fr) Anticorps anti-spicule (s) de sars-cov2 et leurs utilisations

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2023544186

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3194162

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023005684

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2021806447

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021806447

Country of ref document: EP

Effective date: 20230428

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21806447

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112023005684

Country of ref document: BR

Free format text: APRESENTAR NOVO CONTEUDO ELETRONICO DE LISTAGEM DE SEQUENCIAS BIOLOGICAS, UMA VEZ QUE FOI VERIFICADA DIVERGENCIA EM CAMPO 110 E NAO SE ENCONTRA NO FORMATO OMPI ST.25, PADRONIZADO PELA PORTARIA INPI 56/2022.

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112023005684

Country of ref document: BR

Free format text: COM BASE NA PORTARIA INPI 56, DE 27/12/2021, APRESENTAR, EM ATE 60 (SESSENTA) DIAS, NOVO CONTEUDO DE LISTAGEM DE SEQUENCIAS, POIS OS CONTEUDOS APRESENTADOS ENCONTRAM-SE FORA DO PADRAO OMPI ST.25.

ENP Entry into the national phase

Ref document number: 112023005684

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230328

WWW Wipo information: withdrawn in national office

Ref document number: 2021806447

Country of ref document: EP